Why Timelines Break Down in Rare Kidney Drug Development
Enrollment bottlenecks are the dominant cause of delays in kidney‑focused drug development. GlobalData data show low accrual rates drive 47% of nephrology trial suspensions, while median enrollment stretches beyond 15 months—far longer than cardiovascular or metabolic studies. Typical renal trials rely on only three active sites despite an average of 22 sites across the portfolio, creating a structural mismatch between scientific ambition and operational capacity. The problem intensifies for rare diseases, where multiple sponsors compete for a tiny, biopsy‑confirmed patient pool, turning enrollment into a market‑level constraint.
Gilead Outlays $5bn to Acquire ADC Specialist Tubulis
Gilead announced a deal to acquire German ADC specialist Tubulis for up to $5 bn, with $3.15 bn paid upfront and up to $1.85 bn in milestones. The transaction, slated to close in Q2 2026, brings Tubulis' lead candidate TUB‑040—a NaPi2b‑directed topoisomerase‑I inhibitor in...
In the Face of Tariffs, FDA-Approved Drug Manufacturing Deals Are Shifting to Europe
US contract‑manufacturing (CM) deals for FDA‑approved drugs fell sharply last year, marking the biggest decline in five years. Despite a 15% import tariff on European pharmaceuticals, biopharma firms are increasingly outsourcing US‑bound production to European facilities, especially in Germany. By...
Apnimed Obtains up to $150m in Funds for Commercial Launch of AD109
Apnimed secured a senior secured credit facility of up to $150 million from HealthCare Royalty Partners to fund the commercial readiness and potential U.S. launch of AD109, an oral therapy for obstructive sleep apnea. The deal provides an initial $50 million at...
The Hidden Bottleneck in Digital Healthcare: Why Hospital Wireless Networks Are Under Pressure in 2026
Hospitals are racing to adopt AI‑driven diagnostics, remote monitoring, and mobile clinical workflows, but their legacy Wi‑Fi networks are straining under the surge in data traffic. Global AI spending in healthcare is projected to hit $30.9 billion by 2029, fueling high‑resolution...
The Evolving Landscape of Subcutaneous Drug Administration
The pharmaceutical sector is rapidly moving toward subcutaneous (SC) delivery as biologic approvals outpace small‑molecule drugs. While SC administration cuts clinical‑site costs and boosts patient comfort, it suffers from 60‑80% lower bioavailability, demanding higher doses and larger volumes. Innovators are...
CGT’s Next Obstacle: Securing the Leukapheresis Supply Chain
Leukapheresis is emerging as a structural bottleneck as CAR‑T and other cell‑gene therapies expand beyond oncology into autoimmune, cardiovascular and respiratory diseases. The current model relies on a handful of academic centers, creating capacity constraints, geographic inequities, and variability in...
Neurocrine to Acquire Soleno in $2.9bn Transaction
Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $53 per share, valuing the deal at $2.9 bn. The transaction brings Soleno’s FDA‑approved Vykat XR, a first‑in‑class treatment for hyperphagia in Prader‑Willi syndrome, into Neurocrine’s pipeline. Vykat XR posted $190 m revenue...
HNSCC Market Is Expected to Reach to $4.5bn Across 8MM by 2034
GlobalData projects the head and neck squamous cell carcinoma (HNSCC) therapeutics market to grow from $2.0 bn in 2024 to $4.5 bn by 2034, reflecting an 8.4% compound annual growth rate. Immune checkpoint inhibitors (ICIs) dominate, accounting for 69% of 2024 sales...
ACC 2026: Meta-Analysis Supports CagriSema as Superior First-Line Therapy in Obesity
At the ACC 2026 meeting, a Bayesian network meta‑analysis of 2,803 overweight and obese adults showed that the fixed‑dose combination CagriSema outperformed its components, cagrilintide and semaglutide 2.4 mg, across all efficacy measures. CagriSema delivered the greatest absolute and percent weight...
Merck KGaA Acquires JSR Chromatography Business
Merck KGaA has completed the acquisition of JSR Life Sciences' chromatography business, adding advanced Protein A chromatography and Amsphere Protein A resins to its downstream processing suite. The deal brings over 50 employees and a Belgian manufacturing site into Merck’s process solutions...
ACC 2026: Dulaglutide Promotes Coronary Plaque Stabilisation in Patients with T2D
At the American College of Cardiology 2026 meeting, researchers reported that dulaglutide, a weekly GLP‑1 receptor agonist, stabilised coronary plaques in patients with type‑2 diabetes. In a prospective randomised trial of 39 participants with intermediate coronary stenoses, dulaglutide led to...
ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose
At the 2026 ACC Scientific Session, the phase‑II CADENCE trial showed that sotatercept (WINREVAIR) reduced pulmonary vascular resistance in adults with combined post‑ and precapillary pulmonary hypertension linked to HFpEF (CpcPH‑HFpEF). The study randomized 164 patients, median age 75, to...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate Ambagon’s molecular glue candidates for colorectal cancer. The collaboration will use Symeres’ in‑vitro assays, surface plasmon resonance, fluorescence microscopy and a 102‑cell line panel to characterize ternary complex kinetics and downstream pathway...
Navigating Commercial Gaps to Supercharge the UK Life Sciences Sector
The UK government has launched the Life Sciences Sector Plan, a six‑point strategy targeting a $41 bn boost to the industry by 2035. While the nation excels in early‑stage R&D, high claw‑back rates and lengthy trial setups are prompting investors to...
UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies
uBriGene Biosciences has entered a strategic partnership with Cellinfinity BIO to accelerate the development of in‑vivo CAR‑T therapies for both solid tumors and hematologic cancers. The collaboration will apply uBriGene’s LVV Turbo platform, which delivers up to 80% purification recovery...
ACC 2026: Lorundrostat Lowers BP but Raises Hyperkalemia Risk
At the 2026 ACC Scientific Session, Brazilian investigators presented a meta‑analysis of three placebo‑controlled trials (1,060 patients) evaluating lorundrostat in uncontrolled hypertension. Lorundrostat 50 mg reduced systolic blood pressure by 9.08 mm Hg and diastolic by 3.48 mm Hg, while the 100 mg dose achieved an...
From Compliance to Culture: Lessons From a Quality Leader on Pharma’s Next Imperative
Grace Breen, Sharp’s SVP of Quality, argues that pharmaceutical quality must be engineered upstream across the entire supply chain rather than inspected at the end. She promotes a Quality Management Maturity (QMM) model that embeds proactive stewardship, supplier oversight, and...
The Future of Healthcare in America: What to Expect in the Next Decade
Artificial intelligence is becoming a core pillar of U.S. health care, with Deloitte ranking generative AI as a top strategic priority. AI tools are set to streamline diagnostics, clinical decision support, and administrative tasks, improving patient access and reducing in‑person...
The Crucial Role of Payload Linker Innovation in the Growth of ADCs
Antibody‑drug conjugates (ADCs) are becoming a cornerstone of oncology, with the global market expected to reach $65.2 billion by 2031. The number of ADC programs has more than tripled, rising from 557 in 2020 to 1,643 in 2025, driven by advances...
Podcast: European Biotech Rallies Against US and China Powerhouses
The BIO Europe Spring podcast recorded in Lisbon highlighted Europe’s push to reclaim biotech leadership amid dominant US and Chinese pharma giants. Host Robert Barrie distilled insights from investors and executives, emphasizing the continent’s strategic focus on gene‑therapy and mRNA...
J&J’s Darzalex Nets First Self-Administered Cancer Injectable Approval
Johnson & Johnson’s Darzalex (daratumumab) received European Medicines Agency approval for self‑administration, becoming the first oncology injectable cleared for home use. The Type II label change allows patients or caregivers to give the subcutaneous injection after the fifth dose, covering all...
Improving Early Detection and Treatment of Liver Cancer
Early-stage liver cancer survival hinges on timely diagnosis, yet ultrasound and AFP tests miss many cases. Helio Genomics has introduced the HelioLiver blood test, a multi‑analyte cfDNA and protein assay that flags tumor‑associated epigenetic signals earlier than imaging. A new...
MSD and Quotient Collaborate on IBD Drug Targets
Merck (MSD) has entered a multi‑year research partnership with Quotient Therapeutics to uncover new drug targets for inflammatory bowel disease using Quotient’s somatic genomics platform. The deal provides Quotient with $20 million upfront and up to $2.2 billion in regulatory, development and...
Congruence Secures $39.5m to Advance Small Molecule Correctors Pipeline
Congruence Therapeutics announced the completion of a $39.5 million financing round to accelerate its small‑molecule corrector pipeline. The capital, co‑led by Dimension and OrbiMed, will fund a Phase I/Ib study of CGX‑926 for MC4R‑deficient obesity and support IND‑enabling work for candidates...
Quintessence Debuts First ‘Living’ Artificial Cell for CGT Bio-Separation
Quintessence Biotech introduced DACS, the first "living" artificial cell designed to streamline bio‑separation in cell and gene therapy (CGT) manufacturing. The lipid‑particle platform mimics cell size, deformability and antigen presentation, enabling a gravity‑based flotation method that replaces magnetic‑bead workflows. DACS...
Navigating the Valley of Death: A How-To From an Investor’s Perspective
Biotech startups face the notorious "valley of death" as they move from proof‑of‑concept to commercialization, but investors remain active, with a 70.9% jump in venture‑financing deal value between Q2 and Q3 2025. A GlobalData survey shows 39% of respondents are...
R1 Therapeutics Raises $77.5m to Progress AP306 for Hyperphosphatemia
R1 Therapeutics announced a $77.5 million oversubscribed Series A round to advance AP306, a first‑in‑class pan phosphate transporter inhibitor for hyperphosphatemia in chronic kidney disease patients. The funding, led by Abingworth, F‑Prime and DaVita Venture Group, also secured an exclusive global licence...
Transient but Transformative: Sanofi’s mRNA CAR-T Enters in Vivo Race
Sanofi unveiled pre‑clinical data for an in‑vivo CAR‑T platform that delivers mRNA via lipid nanoparticles (LNPs) and a CD8‑targeting VHH nanobody, eliminating the weeks‑long ex‑vivo manufacturing step. The approach achieved tumor suppression in mice with less than 5% liver uptake...
Autologous versus Allogeneic: How Cell Therapy Development Is Changing in Oncology
Autologous CAR‑T therapies dominate the current market but face logistical and clinical challenges. Patients must undergo leukapheresis, endure long vein‑to‑vein times, and often need bridging therapy, which can cause adverse events. To address these issues, companies are shifting toward off‑the‑shelf...
Widespread US Shift From Prescription to OTC Lies in Pharma’s Hands
The FDA is accelerating the shift of prescription medicines to over‑the‑counter status, highlighted by Commissioner Marty Makary’s call for broader OTC availability and the introduction of the Additional Condition for Non‑Prescription Use (ACNU) framework. Former FDA counsel Heidi Gertner stresses...
Biophytis and LynxKite Expand Alliance to Boost AI-Driven Drug Discovery
Biophytis has broadened its alliance with AI specialist LynxKite to fast‑track longevity drug discovery, launching the MASSIVE project that seeks Mas receptor activators for sarcopenia. Backed by Enterprise Singapore, the partnership will augment Biophytis’ computational platform with LynxKite’s chemoinformatics, advanced...
Parkinson’s Research Reaches “Pivotal” Stage, but Barriers Remain
Parkinson’s research has entered a pivotal phase, driven by deeper disease insights and advanced models such as patient‑derived iPSCs. Despite a pipeline of potential disease‑modifying therapies, funding shortfalls and outdated trial endpoints continue to impede progress. Parkinson’s UK’s Virtual Biotech...
PsiQuantum and National Cancer Center Japan Partner on Quantum Computing
PsiQuantum has signed a research agreement with Japan's National Cancer Center to explore utility‑scale quantum computing for oncology drug discovery. The partnership will focus on developing fault‑tolerant quantum algorithms and clinically relevant applications using PsiQuantum's Construct platform. It also brings...
Bavarian Nordic and SII Sign Agreement for Chikungunya Vaccine Production
Bavarian Nordic has signed a manufacturing agreement with the Serum Institute of India to transfer full technology for its chikungunya vaccine, CHIKV VLP (branded Vimkunya). The deal replaces an earlier partnership with Biological E and builds on the companies' existing mpox‑vaccine collaboration....
Tariffs, Uncertainty and Disruption: How Drug Makers and Distributors Can Build Operational Supply Chain Resilience
Tariff announcements create abrupt ordering swings that ripple through pharmaceutical sourcing, pricing and inventory, often leaving manufacturers and distributors with surplus stock or shortages. The article argues that these tariff‑driven shocks become operational risks when companies rely on partial visibility...
Eli Lilly to Invest $3bn in China in Anticipation of Orforglipron Approval
Eli Lilly announced a $3 bn, ten‑year investment to expand its Chinese supply chain for the oral GLP‑1 weight‑loss drug orforglipron. The plan adds oral solid‑dosage capacity in Beijing, expands the Suzhou injection hub, and includes a $200 m CDMO partnership with Pharmaron....
UK Health Authorities Join Forces to Champion Foreign Infectious Disease Trials
UK health agencies and the Wellcome charity have launched a joint initiative to fund high‑quality infectious‑disease clinical trials in Africa, South Asia and Southeast Asia. The program, co‑led by the NIHR, the Foreign Commonwealth Development Office and Wellcome, will prioritize...
Idorsia and Pharmalink Sign Agreement to Distribute Quviviq
Swiss biotech Idorsia has signed an exclusive agreement with UAE‑based Pharmalink Drug Store to distribute its insomnia drug Quviviq (daridorexant) across Kuwait, Oman, Qatar, Bahrain and the United Arab Emirates. Under the deal Idorsia will receive an upfront payment, retain...
Peptides in the Pipeline: How Companies Are Overcoming the Early-Stage Challenges
Peptide therapeutics are booming, with more than 2,000 candidates in discovery and pre‑clinical stages and projected global sales of $91.4 bn by 2025. Companies like Orocidin faced severe synthesis and purification hurdles for their QR‑01 peptide, but Syngene’s custom low‑loading resin...
US Vaccine Manufacturers Set to Lose as RFK Pushes for Weaker Vaccine Mandates
The Trump administration, led by Health Secretary Robert F. Kennedy Jr., plans to eliminate over a third of the CDC childhood vaccine schedule, targeting seven of eleven vaccines. The United States, which produces roughly 36% of global vaccine output, could...
Building for Decades: Dubai’s Long Game in Life Sciences
Dubai is positioning itself as a long‑term hub for healthcare and life sciences through two complementary free‑zone clusters – Dubai Healthcare City (DHCC) and Dubai Science Park (DSP). DHCC is undergoing a $1.3 bn expansion that will create six tightly linked...
Junshi Receives China’s NMPA Acceptance for Toripalimab Injection
Junshi Biosciences has received acceptance from China’s National Medical Products Administration for its subcutaneous toripalimab injection (JS001sc), covering 12 cancer indications. The filing marks the first domestic anti‑PD‑1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage....
NewcelX and Eledon Partner for NCEL-101 Programme
NewcelX has entered a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL‑101 cell therapy for type‑1 diabetes. The partnership integrates NewcelX’s off‑the‑shelf islet replacement product with Eledon’s anti‑CD40L monoclonal antibody, tegoprubart, which has been used in over 100...
GlobalData’s Key Thoughts From World EPA Congress 2026
GlobalData Healthcare attended the World Evidence, Pricing and Access (EPA) congress in Amsterdam, where industry leaders debated mounting market instability. Sessions focused on the impact of the Most Favored Nation (MFN) policy, shifting US tariffs, rapid AI integration, and the...
Multiple Myeloma Awareness Month: The Current and Future Landscape
March marks Multiple Myeloma Awareness Month, spotlighting a disease that affects over 85,000 new patients and 330,000 existing cases across eight major markets in 2026. GlobalData projects MM drug sales to rise from $25.5 bn in 2026 to $29.9 bn by 2032,...
Women First: The Gulf’s New Healthcare Blueprint
Nabta Health, a Dubai‑based startup, is scaling a women‑first preventive‑care platform across the UAE and the wider Middle East‑Africa region. The hybrid model combines a licensed physical clinic, a virtual network of clinicians and AI‑driven risk assessment, and a B2B...
How the AI Shift Is Happening Now in Data Management
The latest generation of AI‑driven tools is transforming clinical trial data management by automating the build of electronic data capture (EDC) systems. Solutions such as CRScube’s AI‑led EDC builder can convert a PDF protocol into a structured database in hours...
Liberate Bio Gains Licences for Myeloid-Specific CAR Design Patents
Liberate Bio announced it has secured both exclusive and non‑exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically engineered for myeloid cells such as monocytes and macrophages. The patents, obtained from Carisma Therapeutics and the University of Pennsylvania,...
Targeted Therapies to Join Chemo as Oncology Treatment Backbone
Targeted therapies are reshaping oncology, yet chemotherapy remains essential. Immune checkpoint inhibitors like Keytruda generate $31.7 bn sales in 2025 and cover more than 40 indications. The FDA granted 63 antibody‑drug conjugate review designations in 2024, nearly double the previous peak....
